Fondaparinux also significantly reduced the rate of adjudicated fatal PE [0 patients (0.0%) vs 5 patients (1.2%), respectively].
Fondapariinuks langetas märkimisväärselt ka patoanatoomiliselt tõestatud fataalseid PE juhtumeid [vastavalt 0 patsienti (0, 0%) vs 5 patsienti (1, 2%)].